FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125052010> ?p ?o ?g. }

• W3125052010 endingPage "1558" @default.
• W3125052010 startingPage "1548" @default.
• W3125052010 abstract "BACKGROUND: Cardiac surgery with cardiopulmonary bypass (CPB) is associated with a high risk of postoperative acute kidney injury (AKI). Due to limitations of current diagnostic strategies, we sought to determine whether free hemoglobin (fHb) ratio (ie, levels of fHb at the end of CPB divided by baseline fHb) could predict AKI after on-pump cardiac surgery. METHODS: This is a secondary analysis of a randomized controlled trial comparing the effect of nitric oxide (intervention) versus nitrogen (control) on AKI after cardiac surgery (NCT01802619). A total of 110 adult patients in the control arm were included. First, we determined whether fHb ratio was associated with AKI via multivariable analysis. Second, we verified whether fHb ratio could predict AKI and incorporation of fHb ratio could improve predictive performance at an early stage, compared with prediction using urinary biomarkers alone. We conducted restricted cubic spline in logistic regression for model development. We determined the predictive performance, including area under the receiver-operating-characteristics curve (AUC) and calibration (calibration plot and accuracy, ie, number of correct predictions divided by total number of predictions). We also used AUC test, likelihood ratio test, and net reclassification index (NRI) to compare the predictive performance between competing models (ie, fHb ratio versus neutrophil gelatinase–associated lipocalin [NGAL], N-acetyl-β-d-glucosaminidase [NAG], and kidney injury molecule-1 [KIM-1], respectively, and incorporation of fHb ratio with NGAL, NAG, and KIM-1 versus urinary biomarkers alone), if applicable. RESULTS: Data stratified by median fHb ratio showed that subjects with an fHb ratio >2.23 presented higher incidence of AKI (80.0% vs 49.1%; P = .001), more need of renal replacement therapy (10.9% vs 0%; P = .036), and higher in-hospital mortality (10.9% vs 0%; P = .036) than subjects with an fHb ratio ≤2.23. fHb ratio was associated with AKI after adjustment for preestablished factors. fHb ratio outperformed urinary biomarkers with the highest AUC of 0.704 (95% confidence interval [CI], 0.592-0.804) and accuracy of 0.714 (95% CI, 0.579-0.804). Incorporation of fHb ratio achieved better discrimination (AUC test, P = .012), calibration (likelihood ratio test, P < .001; accuracy, 0.740 [95% CI, 0.617-0.832] vs 0.632 [95% CI, 0.477-0.748]), and significant prediction increment (NRI, 0.638; 95% CI, 0.269-1.008; P < .001) at an early stage, compared with prediction using urinary biomarkers alone. CONCLUSIONS: Results from this exploratory, hypothesis-generating retrospective, observational study shows that fHb ratio at the end of CPB might be used as a novel, widely applicable biomarker for AKI. The use of fHb ratio might help for an early detection of AKI, compared with prediction based only on urinary biomarkers." @default.
• W3125052010 created "2021-02-01" @default.
• W3125052010 creator A5006094306 @default.
• W3125052010 creator A5006181213 @default.
• W3125052010 creator A5016631374 @default.
• W3125052010 creator A5033813700 @default.
• W3125052010 creator A5042363389 @default.
• W3125052010 creator A5079746187 @default.
• W3125052010 date "2021-01-21" @default.
• W3125052010 modified "2023-10-18" @default.
• W3125052010 title "Free Hemoglobin Ratio as a Novel Biomarker of Acute Kidney Injury After On-Pump Cardiac Surgery: Secondary Analysis of a Randomized Controlled Trial" @default.
• W3125052010 cites W1971799714 @default.
• W3125052010 cites W1991115314 @default.
• W3125052010 cites W2003034890 @default.
• W3125052010 cites W2033028860 @default.
• W3125052010 cites W2055105222 @default.
• W3125052010 cites W2056867548 @default.
• W3125052010 cites W2104682999 @default.
• W3125052010 cites W2121271836 @default.
• W3125052010 cites W2122036831 @default.
• W3125052010 cites W2127238074 @default.
• W3125052010 cites W2133022545 @default.
• W3125052010 cites W2141413316 @default.
• W3125052010 cites W2142909616 @default.
• W3125052010 cites W2159704023 @default.
• W3125052010 cites W2168729190 @default.
• W3125052010 cites W2213168893 @default.
• W3125052010 cites W2264500817 @default.
• W3125052010 cites W2403504138 @default.
• W3125052010 cites W2411966586 @default.
• W3125052010 cites W2416660207 @default.
• W3125052010 cites W2467711571 @default.
• W3125052010 cites W2541178389 @default.
• W3125052010 cites W2550172802 @default.
• W3125052010 cites W2610654630 @default.
• W3125052010 cites W2753430773 @default.
• W3125052010 cites W2775713727 @default.
• W3125052010 cites W2809511603 @default.
• W3125052010 cites W2809934632 @default.
• W3125052010 cites W2887265841 @default.
• W3125052010 cites W2913019560 @default.
• W3125052010 cites W2948385156 @default.
• W3125052010 cites W2951853690 @default.
• W3125052010 cites W2973051733 @default.
• W3125052010 cites W3022423927 @default.
• W3125052010 cites W3133528108 @default.
• W3125052010 cites W4231980339 @default.
• W3125052010 cites W4238494775 @default.
• W3125052010 doi "https://doi.org/10.1213/ane.0000000000005381" @default.
• W3125052010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8154645" @default.
• W3125052010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33481401" @default.
• W3125052010 hasPublicationYear "2021" @default.
• W3125052010 type Work @default.
• W3125052010 sameAs 3125052010 @default.
• W3125052010 citedByCount "15" @default.
• W3125052010 countsByYear W31250520102021 @default.
• W3125052010 countsByYear W31250520102022 @default.
• W3125052010 countsByYear W31250520102023 @default.
• W3125052010 crossrefType "journal-article" @default.
• W3125052010 hasAuthorship W3125052010A5006094306 @default.
• W3125052010 hasAuthorship W3125052010A5006181213 @default.
• W3125052010 hasAuthorship W3125052010A5016631374 @default.
• W3125052010 hasAuthorship W3125052010A5033813700 @default.
• W3125052010 hasAuthorship W3125052010A5042363389 @default.
• W3125052010 hasAuthorship W3125052010A5079746187 @default.
• W3125052010 hasBestOaLocation W31250520101 @default.
• W3125052010 hasConcept C126322002 @default.
• W3125052010 hasConcept C126894567 @default.
• W3125052010 hasConcept C141071460 @default.
• W3125052010 hasConcept C151956035 @default.
• W3125052010 hasConcept C164705383 @default.
• W3125052010 hasConcept C168563851 @default.
• W3125052010 hasConcept C185592680 @default.
• W3125052010 hasConcept C2778789114 @default.
• W3125052010 hasConcept C2778881276 @default.
• W3125052010 hasConcept C2780472472 @default.
• W3125052010 hasConcept C2781197716 @default.
• W3125052010 hasConcept C55493867 @default.
• W3125052010 hasConcept C58471807 @default.
• W3125052010 hasConcept C71924100 @default.
• W3125052010 hasConcept C76318530 @default.
• W3125052010 hasConcept C77411442 @default.
• W3125052010 hasConceptScore W3125052010C126322002 @default.
• W3125052010 hasConceptScore W3125052010C126894567 @default.
• W3125052010 hasConceptScore W3125052010C141071460 @default.
• W3125052010 hasConceptScore W3125052010C151956035 @default.
• W3125052010 hasConceptScore W3125052010C164705383 @default.
• W3125052010 hasConceptScore W3125052010C168563851 @default.
• W3125052010 hasConceptScore W3125052010C185592680 @default.
• W3125052010 hasConceptScore W3125052010C2778789114 @default.
• W3125052010 hasConceptScore W3125052010C2778881276 @default.
• W3125052010 hasConceptScore W3125052010C2780472472 @default.
• W3125052010 hasConceptScore W3125052010C2781197716 @default.
• W3125052010 hasConceptScore W3125052010C55493867 @default.
• W3125052010 hasConceptScore W3125052010C58471807 @default.
• W3125052010 hasConceptScore W3125052010C71924100 @default.
• W3125052010 hasConceptScore W3125052010C76318530 @default.
• W3125052010 hasConceptScore W3125052010C77411442 @default.

• next